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Abstract: Donation after circulatory death (DCD) could improve donor heart availability;
however, warm ischemia-reperfusion injury raises concerns about graft quality. Mechanical
postconditioning (MPC) may limit injury, but mechanisms remain incompletely characterized.
Therefore, we investigated the roles of glucose metabolism and key signaling molecules in MPC using
an isolated rat heart model of DCD. Hearts underwent 20 min perfusion, 30 min global ischemia,
and 60 min reperfusion with or without MPC (two cycles: 30 s reperfusion—30 s ischemia). Despite
identical perfusion conditions, MPC either significantly decreased (low recovery = LoR; 32 ± 5%;
p < 0.05), or increased (high recovery = HiR; 59 ± 7%; p < 0.05) the recovery of left ventricular
work compared with no MPC (47 ± 9%). Glucose uptake and glycolysis were increased in HiR vs.
LoR hearts (p < 0.05), but glucose oxidation was unchanged. Furthermore, in HiR vs. LoR hearts,
phosphorylation of raptor, a downstream target of AMPK, increased (p < 0.05), cytochrome c release
(p < 0.05) decreased, and TNFα content tended to decrease. Increased glucose uptake and glycolysis,
lower mitochondrial damage, and a trend towards decreased pro-inflammatory cytokines occurred
specifically in HiR vs. LoR MPC hearts, which may result from greater AMPK activation. Thus, we
identify endogenous cellular mechanisms that occur specifically with cardioprotective MPC, which
could be elicited in the development of effective reperfusion strategies for DCD cardiac grafts.
Keywords: cardiac ischemia reperfusion injury; donation after circulatory death; postconditioning;
contractile function; glucose metabolism
1. Introduction
For patients with end-stage heart failure, a heart transplantation is the gold-standard treatment [1].
Unfortunately, the supply of cardiac grafts is insufficient to cover the increasing demand [2]. Donation
after circulatory death (DCD) could substantially increase donor heart availability; however, DCD hearts
inevitably undergo warm, unprotected ischemia and reperfusion, which raise concerns about graft
quality. Nonetheless, the feasibility of adult heart transplantation with DCD has been demonstrated
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in recent reports [3–5]. With DCD, increases in adult heart transplant activity of 15–33% have been
observed in Australia and the UK since the implementation of DCD heart transplantation in their
corresponding institutions [6,7]. As such, therapeutic strategies to optimize graft recovery following
ischemia and reperfusion are now needed for the adoption of DCD heart transplantation in a safe and
widespread manner. Because interventions prior to graft procurement are limited for ethical reasons in
DCD, therapies, such as recruitment of endogenous protective mechanisms, at the time of reperfusion
have the potential to provide considerable clinical impact by limiting graft ischemia-reperfusion injury.
Mechanical postconditioning (MPC; brief, intermittent periods of ischemia applied at the onset of
reperfusion) can limit ischemia-reperfusion injury (IRI) by eliciting the heart’s endogenous protective
mechanisms. Various reports have demonstrated the efficacy of MPC in limiting lethal reperfusion
injury in experimental acute myocardial infarction [8–10]; however, clinical trials have been unable
to demonstrate convincing protective effects [11]. On one hand, the lack of effective clinical
cardioprotection may result from technical aspects, such as inability to implement conditioning
in a timely manner, as well as patient co-morbidities and co-medications that interfere with the effective
recruitment of conditioning mechanisms [11]. In DCD, reperfusion is a clinically scheduled, timely
intervention and co-morbidities and co-medications are limited through donor selection. Therefore,
approaches such as MPC may provide more consistent protection in this context. On the other hand,
the cardioprotective efficacy of MPC varies according to the experimental model and specific conditions
(i.e., energy substrate availability [12], age [13], in vivo vs. ex vivo [14], Langendorff vs. working
mode [15], ischemic temperature [15] or postconditioning algorithm [16]). This variability highlights
our incomplete understanding of the precise mechanisms responsible for the cardioprotective effects of
MPC. As such, its value may lie in its use as an experimental tool for the identification of endogenous
cardiac mechanisms as targets amenable to pharmacological intervention, rather than as a potential
therapeutic approach.
MPC has been reported to provide cardioprotection through several mechanisms. The reperfusion
injury salvage kinase (RISK) pathway, comprising the phosphoinositide 3-kinase (PI3K)/Akt and
extracellular signal-regulated kinase (Erk) 1/2 pro-survival kinase cascades, as well as the survivor
activating factor enhancement (SAFE) pathway may attenuate reperfusion-induced cell death via the
preservation of mitochondrial integrity [17,18]. 5′AMP-activated protein kinase (AMPK) has also
been proposed to contribute to some MPC-induced cardioprotective effects; however, it has not been
clearly designated as a mediator of MPC, as its activity has not been evaluated [19]. MPC may also
provide cardioprotection via the reduction in pro-inflammatory responses by reducing accumulation of
neutrophils in the myocardial infarction zone [20], and/or decreasing plasma tumor necrosis factor alpha
(TNFα) levels [21]. Interestingly, AMPK also protects against TNFα-induced cardiac cell death [22]
and reduces macrophage inflammation [23]; however, its role in anti-inflammatory effects induced by
MPC-induced cardioprotection has not been investigated.
Despite the fact that energy metabolism plays a fundamental role in IRI and may be affected
by the signaling pathways stimulated by MPC, few investigators have addressed the role of energy
metabolism in MPC-induced cardioprotection. Reperfusion of an ischemic area typically results in
the rapid recovery of fatty acid oxidation, which inhibits glucose use, particularly its oxidation [24].
Importantly, in DCD, as well as in other clinical situations of warm ischemia-reperfusion, the heart
is exposed to high levels of free fatty acids prior to warm ischemia [25], which can be detrimental
for post-ischemic function [26]. Shifting energy substrate metabolism away from fatty acid oxidation
and towards glucose use during early reperfusion has been proposed to limit IRI and improve
subsequent contractile recovery [27]. Interestingly, activation of Akt and AMPK, both implicated in
MPC-induced cardioprotection, would be expected to promote glucose metabolism [28,29]; however,
these mechanisms have not yet been investigated.
We therefore aimed to investigate the effects of MPC on glucose metabolism and its key regulatory
pathways during early reperfusion, in order to better characterize endogenous mechanisms of
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cardioprotection in an isolated, working rat heart model of DCD that includes clinically relevant
circulating levels of free fatty acids prior to warm ischemia.
2. Results
2.1. Baseline Characteristics
Baseline characteristics and sample sizes for experimental Series A and B are shown in Table 1.
Within each series, no difference among the experimental groups was observed.
Table 1. Baseline characteristics Series A and B. BW, body weight; CF, coronary flow; CO, cardiac
output; DP, developed pressure; dP/dt max, maximum first derivative of LV pressure; dP/dt min,
minimum first derivate of LV pressure; HiR, high recovery; HR, heart rate; HW, heart weight; IR,
ischemia reperfusion; LoR, low recovery; LV work, left-ventricular work (HR-DP product); MPC,
mechanical postconditioning; NI, no ischemia. Data are expressed as mean ± standard deviation.
Variable Series A Series B
NI IR HiR MPC LoR MPC NI IR HiR MPC LoR MPC
Number of
hearts 7 8 11 7 6 6 7 10
BW (g) 377 ± 64 364 ± 23 350 ± 28 356 ± 26 341 ± 16 347 ± 17 373 ± 31 356 ± 23
HW (g) 1.69 ± 0.26 1.57 ± 0.09 1.64 ± 0.15 1.58 ± 0.20 1.50 ± 0.10 1.60 ± 0.20 1.75 ± 0.24 1.64 ± 0.18
LV work (mmHg
∗ beats ∗min−1)
33,507 ±
1895
33,673 ±
2677
32,760 ±
2468
34,036 ±
2007
36,990 ±
1917
33,625 ±
3674
33,573 ±
5043
33,727 ±
1674
HR (beats ∗
min−1) 275 ± 43 266 ± 15 263 ± 16 259 ± 14 276 ± 24 264 ± 30 247 ± 38 264 ± 21
DP (mmHg) 124 ± 15 127 ± 10 125 ± 9 132 ± 6 135 ± 9 128 ± 12 136 ± 11 128 ± 8
dP/dt min
(mmHg ∗ s−1) −4313 ± 621 −4492 ± 991 −4173 ± 188 −4598 ± 622 −4639 ± 356 −4457 ± 906 −4797 ± 583 −5048 ± 1272
dP/dt max
(mmHg ∗ s−1) 4354 ± 526 4475 ± 483 4361 ± 506 4621 ± 244 5046 ± 411 4246 ± 484 4673 ± 556 4498 ± 590
CO (mL ∗min−1) 64 ± 14 61 ± 11 61 ± 7 63 ± 4 66 ± 6 64 ± 11 68 ± 12 65 ± 9
CF (mL ∗min−1) 32 ± 5 32 ± 5 30 ± 3 32 ± 4 29 ± 4 27 ± 8 32 ± 6 33 ± 4
2.2. Post-Ischemic Cardiac Functional Recovery
Among hearts that underwent ischemia, those that were treated with MPC demonstrated
substantially more variability during recovery than those ischemic hearts without treatment (IR).
More specifically, MPC hearts, despite the same protocol, tended to recover relatively well (>48%
left ventricular (LV) work recovery) or rather poorly (<38%; Figure 1A). The clear separation in
recovery observed in hearts subjected to MPC allowed us to designate two recovery subgroups: MPC
high-recovery (HiR) and low-recovery (LoR) subgroups, based on a cut-off value of 45% LV work
recovery at 60 min reperfusion (or 25% LV work recovery at 15 min reperfusion).
Absolute values of cardiac functional parameters during reperfusion are represented in
Figure 1B–D. As expected, post-ischemic cardiac function was significantly decreased in IR hearts
compared to NI hearts in terms of LV work, cardiac output, dP/dt max (p < 0.05; Figure 1B–D) as well
as heart rate, developed pressure and dP/dt min (p < 0.05; data not shown), but not coronary flow (data
not shown). MPC significantly increased (HiR) or decreased (LoR) left ventricular work at 60 min
reperfusion compared to IR hearts (p < 0.05 for both; Figure 1B). Significant differences between HiR
and LoR MPC hearts were observed for LV work and cardiac output at all time points, and for dP/dt
max at 40 and 60 min reperfusion (all p < 0.05; Figure 1B–D).
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Figure 1. Post-ischemic contractile recovery. (A) Distribution of left-ventricular work (LV work
= developed pressure × heart rate [mmHg × beats × min−1]) recovery (LV work value at 60 min
reperfusion expressed as a percentage of mean baseline value). Two MPC subgroups were observed:
high (HiR) and low (LoR) recovery; (B) LV work (percentages: LV work values at 60 min reperfusion
expressed as a percentage of mean baseline value); (C) Cardiac output; (D) dP/dt max (maximum
first derivative of LV pressure). IR, ischemia reperfusion; MPC, mechanical postconditioning; NI, no
ischemia. Data are expressed as mean ± standard deviation. * p < 0.05 vs. IR, ‡ p < 0.05 LoR MPC vs.
HiR MPC (n = 7–11/group).
2.3. Markers of Cell Damage
Markers of cellular (cardiac troponin I (cTnI) and heart-type fatty acid binding protein (H-FABP))
and mitochondrial (cytochrome c (cyt c)) damage were measured at 10 min reperfusion. Release of
cTnI, H-FABP and cyt c appeared greater in IR vs. NI hearts, but reached statistical significance only for
H-FABP and cyt c (p < 0.05 for both, p = 0.1104 for cTnI; Figure 2). LoR MPC hearts, but not HiR MPC
hearts, released more cyt c and cTnI compared to IR (p < 0.05 for both). Furthermore, a significantly
greater cyt c release (p < 0.05) as well as a tendency for a greater cTnI and H-FABP release (p = 0.0555
and p = 0.1293 respectively) were observed in LoR vs. HiR MPC hearts.
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Figure 2. Release of circulating markers of cell death and mitochondrial damage at 10 min reperfusion.
(A) cardiac troponin I (cTnI); (B) heart-type fatty acid binding protein (H-FABP); (C) cytochrome c (Cyt c).
HiR, high recovery; IR, ischemia reperfusion; LoR, low recovery; MPC, mechanical postconditioning;
NI, no ischemia. Data are expressed as median, 25–75 percentiles and range. * p < 0.05 vs. IR, ‡ p < 0.05
LoR MPC vs. HiR MPC (n = 6–10/group).
2.4. Post-Ischemic Metabolic Recovery
Higher rates of glycolysis during the 60 min reperfusion period were observed in IR compared to
NI hearts (p < 0.05). Among hearts subjected to ischemia, glycolysis rates were highest in HiR hearts
(p < 0.05 vs. IR and vs. LoR; Figure 3A). Glucose oxidation rates during reperfusion on the other hand,
were significantly decreased in HiR MPC vs. IR hearts (p < 0.05; Figure 3B), but not different in LoR
MPC vs. IR hearts.
Figure 3. Post-ischemic metabolic recovery. (A) Rates of glycolysis; (B) Rates of glucose oxidation;
(C) Lactate accumulation (net change) in recirculating perfusate; (D) Oxygen efficiency [LV work/oxygen
consumption] at 15 min reperfusion; (E) Glycogen content at 60 min reperfusion; (F) Glucose uptake
(calculated) at 60 min reperfusion. HiR, high recovery; IR, ischemia reperfusion; LoR, low recovery;
MPC, mechanical postconditioning; NI, no ischemia. Data are expressed as mean ± standard deviation
(A–C) or as median, 25–75 percentiles and range (D–F). * p < 0.05 vs. IR, ‡ p < 0.05 LoR MPC vs. HiR
MPC (n = 4–11/group).
As expected, less lactate was released in NI vs. ischemic hearts (p < 0.05 vs. IR) at all reperfusion
time points (Figure 3C). No significant differences were observed among hearts subjected to ischemia.
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Oxygen efficiency, the ratio of LV work to oxygen consumption, tended to be lower in IR vs. NI
hearts (p = 0.0570), and was significantly lower in LoR vs. HiR MPC hearts (p < 0.05; Figure 3D).
Glycogen content at the end of reperfusion was lower in LoR MPC hearts compared to IR (p < 0.05;
Figure 3E) and glucose uptake was decreased in LoR vs. HiR MPC hearts (p < 0.05; Figure 3F).
2.5. Intracellular Signaling Pathways
Western blots were performed at 15 min reperfusion to investigate the activation of key signaling
pathways during early reperfusion. AMPK phosphorylation was increased in ischemic hearts
(p < 0.05 IR vs. NI), but was not different between IR, HiR and LoR MPC (Figure 4A). Phosphorylation
of various downstream targets of AMPK are presented in Figure 4B-E (ACC, AS160, raptor, p38 MAPK).
Raptor phosphorylation was significantly higher in HiR vs. LoR MPC hearts (p < 0.05), and although
not statistically significant, AS160 demonstrated a tendency for greater phosphorylation in HiR vs.
LoR MPC hearts (p = 0.077). As a representative of the SAFE pathway, STAT3 phosphorylation was
measured. No differences were observed between experimental groups (Figure 4F). Upon reperfusion
following ischemia, molecules of the RISK (Akt, Erk1, GSK3β) and mTOR pathways (mTOR, p70S6K,
4E-BP1) demonstrated significantly greater phosphorylation than those without ischemia (p < 0.05 IR
vs. NI for all; Figure 5). No significant differences in the phosphorylation pattern of these molecules
could be observed between IR, HiR MPC and LoR MPC. However, a tendency for greater mTOR
phosphorylation could be observed in HiR vs. LoR MPC hearts (p = 0.078).
Figure 4. Activation of key signaling molecules—AMPK and Survivor Activating Factor Enhancement
(SAFE) pathway. Representative Western blots for phosphorylated and total proteins in top panels
and ratios of phosphorylated to total proteins for: (A) AMP-activated protein kinase (AMPK) [Thr172];
(B) acetyl-CoA carboxylase (ACC) [Ser79]; (C) Akt substrate of 160 kDa (AS160) [Thr642]; (D) regulatory
associated protein of mTOR (raptor) [Ser792]; (E) p38 mitogen-activated protein kinase (p38 MAPK)
[Thr180/Tyr182]; (F) signal transducer and activator of transcription 3 (STAT3) [Tyr705]. HiR, high
recovery; IR, ischemia reperfusion; LoR, low recovery; MPC, mechanical postconditioning; NI, no
ischemia. Data are expressed as median, 25–75 percentiles and range. * p < 0.05 vs. IR, ‡ p < 0.05 LoR
MPC vs. HiR MPC (n = 5–10/group).
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Figure 5. Activation of key signaling molecules—Reperfusion Injury Salvage Kinase (RISK) and mTOR
pathway. Representative Western blots for phosphorylated and total proteins in top panels and ratios of
phosphorylated to total proteins for: (A) Akt [Ser473]; (B) extracellular signal-regulated kinase 1 (Erk1)
[Thr202]; (C) glycogen synthase kinase 3 beta (GSK3β) [Ser9]; (D) mammalian target of rapamycin
(mTOR) [Ser2448]; (E) ribosomal protein S6 kinase (p70S6K) [Thr389]; (F) eukaryotic translation
initiation factor 4E-binding protein 1 (4E-BP1) [Thr37/46]. HiR, high recovery; IR, ischemia reperfusion;
LoR, low recovery; MPC, mechanical postconditioning; NI, no ischemia. Data are expressed as median,
25–75 percentiles and range. * p < 0.05 vs. IR (n = 4–7/group).
2.6. Cytokine Content
The cardiac content of pro- and anti-inflammatory cytokines was determined at 15 min reperfusion
(Figure 6). TNFα and interleukin-6 (IL-6) levels tended to be decreased in HiR MPC hearts compared
to LoR MPC hearts.
Figure 6. Cardiac cytokine content at 15 min reperfusion. (A) Tumor necrosis factor alpha (TNFα);
(B) interleukin 6 (IL-6); (C) interleukin 10 (IL-10). HiR, high recovery; IR, ischemia reperfusion; LoR,
low recovery; MPC, mechanical postconditioning; NI, no ischemia. Data are expressed as median,
25–75 percentiles and range. (n = 5–8/group).
3. Discussion
Using an isolated rat heart model of DCD, we demonstrate that MPC can have deleterious—as
well as protective—effects on post-ischemic cardiac recovery, and is therefore not a safe strategy
to use with DCD cardiac grafts. Importantly, the emergence of HiR and LoR MPC subgroups,
with significantly different contractile recoveries despite identical treatment, could help to identify
endogenous, protective mechanisms that are specifically associated with cardioprotection. Indeed,
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MPC reduced functional recovery, induced greater mitochondrial damage, and increased cell death in
LoR hearts. However, MPC improved functional recovery while increasing rates of glycolysis and
reducing glucose oxidation in HiR hearts. In parallel with improved contractile function in HiR vs.
LoR MPC hearts, glucose uptake, glycolysis, mitochondrial preservation, and oxygen efficiency were
increased. Our findings support a role for AMPK activation in MPC-induced protective effects, likely
via the phosphorylation of AS160, in increasing glucose uptake and glycolysis. Furthermore, reduced
levels of circulating cyt c and tendencies for lower cardiac TNFα in HiR vs. LoR MPC hearts are
consistent with a mechanism involving AMPK activation. Taken together, we identify mechanisms
that occur specifically with MPC only when it provides cardioprotection, which could be used towards
the development of pharmacologic targets for safe, effective, and reliable reperfusion strategies to help
ensure optimal function of DCD cardiac grafts.
Conditioning of the heart after the onset of ischemia, for example: MPC or remote conditioning,
is particularly attractive in settings when ischemia cannot be anticipated, and has previously been
investigated in the context of myocardial infarction. Many pre-clinical studies to ‘condition’ the
heart have demonstrated successful protection against ischemia-reperfusion injury. However,
the cardioprotective efficacy of MPC varies according to the experimental model and specific
conditions [12–16] and translation into clinics has not yet been successful [11,30]. Just recently,
an international randomized controlled trial on the effect of remote ischemic conditioning
(CONDI-2/ERIC-PPCI trial) in patients with acute myocardial infarction reported no improvement in
clinical outcome [31]. These recent findings further stress our incomplete understanding of cardiac
conditioning mechanisms. Problematic issues mentioned for the translatability of pre-clinical studies,
as timely intervention or co-medications [11], will be less of a problem in a DCD setting compared
to myocardial infarction. In our study, with the emergence of high and low subgroups with MPC,
we can identify MPC-induced effects that are specifically associated with improved cardiac recovery,
thereby providing new mechanistic information. We reveal that AMPK activation (indicated by
greater raptor phosphorylation) was prolonged and glucose metabolism (especially glucose uptake and
glycolysis) was stimulated by MPC only when functional recovery increased, and not when functional
recovery decreased. As such, the pharmacologic stimulation of AMPK and glucose metabolism
during DCD heart procurement might be a promising approach for limiting IRI. In human DCD heart
transplantation, pharmacologic cardioprotection is already used—erythropoietin and the nitric oxide
donor glyceryl trinitrate are provided in the cardioplegia [3]. Therefore, the pharmacologic stimulation
of AMPK and glucose metabolism (for example, with metformin [32]) could be complementary and
would be interesting to investigate. Importantly, in clinical DCD protocols, the heart will be reperfused
(isolated) on an ex-situ perfusion machine [3] and thus, the potential detrimental impact of drugs or
drug doses on other organ systems will be limited.
MPC reduced recovery in some hearts (LoR MPC) compared with hearts subjected to ischemia
and reperfusion without MPC. In these hearts, functional recovery decreased, while indicators
of mitochondrial damage and cell death increased, consistent with reperfusion-injury-induced
mitochondrial damage and subsequent cell death [33,34]. Interestingly, activation of the RISK pathway
(Akt and Erk) was increased during early reperfusion in all hearts exposed to ischemia (compared
to non-ischemic controls), but was not further elevated by the application of MPC, suggesting that
conditioning mechanisms that are dependent on the RISK pathway are already maximally elicited
under these conditions, and cannot be further stimulated by MPC. Thus, we cannot attribute the lack
of cardioprotection in LoR MPC hearts to ineffective RISK pathway activation. In our study, hearts
underwent 30 min normothermic, global ischemia, which is severe, but corresponds with the maximal
warm ischemic time permitted in clinical DCD heart transplantation protocols [35]. Under these
conditions, it would be reasonable to speculate that, for some hearts, we have exceeded the ischemic
time window for which MPC is able to provide effective cardioprotection, and that the additional short
intervals of ischemia during MPC exacerbate IRI.
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However, in other hearts, MPC improved recovery after ischemia compared with non-MPC-treated
hearts. Contractile recovery increased in HiR MPC vs. IR hearts in parallel with changes in glucose
metabolism. Our findings of greater glucose uptake and glycolysis are consistent with those of Correa
et al., who reported increases in glycolysis and GLUT4 translocation during early reperfusion in
association with MPC-induced cardioprotective effects in isolated rat hearts [36]. Furthermore, we
observed a decrease in glucose oxidation in HiR MPC vs. IR hearts during reperfusion. To our
knowledge, effects of MPC have not previously been reported on glucose oxidation. The increased
glycolysis but lower glucose oxidation rates in hearts with higher recovery suggests greater uncoupling
between glycolysis and glucose oxidation in HiR MPC hearts, which is rather unexpected, as this
results in the accumulation of intracellular protons [37]. This accumulation could lead to a decreased
cardiac function, as more ATP would be needed for normalization of intracellular pH and therefore less
ATP will be available for myocardial contraction [37]. On the other hand, increased glycolysis may be
beneficial as glycolytically-derived ATP plays a critical role in maintaining calcium homeostasis during
reperfusion [38], and thereby helps to prevent intracellular calcium overload, which could induce
cardiomyocyte death by hypercontracture or mitochondrial damage [34]. Taken together, it appears
that increased glucose uptake and glycolysis occur in parallel with MPC-induced improvements in
contractile recovery during early reperfusion; however, precisely how these alterations influence
cardiac recovery remains to be determined.
In our study, MPC did not consistently provide cardioprotection, but resulted in the emergence
of recovery subgroups. The precise reason underlying differing responses to MPC, despite identical
treatment, remains unclear. Since no subgroups were observed in NI or IR groups, we can exclude
artefacts arising from the isolated heart preparations or perfusion technique. In a similar model, it has
been reported that subgroups can occur during reperfusion and that these subgroups depend on
energy substrate availability [12]. A role for energy metabolism in the development of subgroups is
consistent with our findings of differing glucose metabolism in HiR vs. LoR MPC hearts. Notably,
the existence of two subgroups in our study provides the unique opportunity to directly compare
high- vs. low-recovery hearts that were all subjected to MPC, and may therefore aid in pinpointing
critical MPC-induced protective mechanisms, while eliminating MPC-associated changes that do not
contribute to cardioprotection.
Differences between high and low recovery subgroups may be particularly useful for improving our
understanding of cardioprotective mechanisms (Figure 7). In our study, glucose uptake and glycolysis
were significantly higher in HiR vs. LoR MPC hearts. One mechanism for increased glucose uptake
and glycolysis is through activation of AMPK [39], which has been implicated in MPC, but not clearly
designated as a mediator, as its activity was not evaluated [19]. In our study, AMPK phosphorylation
levels between HiR and LoR MPC groups were similar at 15 min reperfusion, but it is important to
note that AMPK phosphorylation decreases rapidly in this model upon reperfusion (unpublished
data). As such, and given the possibility of allosteric activation of AMPK [40], downstream targets of
AMPK were also evaluated. Greater phosphorylation of raptor, a direct substrate of AMPK [41], in HiR
vs. LoR MPC hearts supports the concept that AMPK activation is prolonged after ischemia in HiR
MPC, but not LoR MPC hearts. AMPK can phosphorylate AS160 [29], promoting the translocation of
GLUT4 to the plasma membrane and stimulating glucose uptake [42]. Phosphorylation of the Rab
GTPase-activating protein AS160 (also known as TBC1D4) also tended to increase in HiR vs. LoR
MPC hearts. To our knowledge, MPC-induced activation of AS160 has not been reported. Akt can
also phosphorylate AS160 [29], however, we did not observe any difference in Akt phosphorylation or
its downstream targets between HiR and LoR MPC groups. It is thus tempting to speculate that the
increased AS160 phosphorylation in HiR vs. LoR MPC hearts underlies increases in glucose uptake
and glycolysis downstream of AMPK in our study.
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Figure 7. Potential mechanism for MPC-induced cardioprotection. HiR MPC hearts presented better
functional post-ischemic recovery, as well as reduced release of cell death markers and lower tissue
levels of pro-inflammatory cytokines, compared with LoR MPC hearts. Increased AMPK activation
(raptor and AS160), greater glucose uptake and glycolysis, and less mitochondrial damage may all
contribute to the cardioprotective effects of MPC. No evidence for the involvement of the SAFE or
RISK pathway was observed (as indicated by the “x” in the figure) under these conditions. ↑: higher
in HiR vs. LoR MPC hearts. ↓: lower in HiR vs. LoR MPC hearts. ↑ or ↓with *: p < 0.05 between
HiR and LoR MPC hearts, ↑ or ↓ without * indicate non-significant tendency between HiR and LoR
MPC hearts. Arrows (continuous lines) connecting boxes: demonstrated relationship. Arrows (dashed
lines) connecting boxes: expected/proposed relationship. AMPK, AMP-activated protein kinase; AS160,
Akt substrate of 160 kDa; cTnI, cardiac troponin I; cyt c, cytochrome c; HiR, high recovery; LoR, low
recovery; MPC, mechanical postconditioning; raptor; regulatory associated protein of mTOR; RISK,
reperfusion injury salvage kinase; SAFE, survivor activating factor enhancement; TNFα, tumor necrosis
factor alpha.
Mitochondria were better preserved in HiR vs. LoR MPC hearts, as indicated by lower cyt c
release. Consistent with these findings, HiR MPC hearts were more oxygen-efficient (greater LV
work performed per oxygen consumed) than LoR MPC hearts during early reperfusion. Importantly,
MPC can inhibit irreversible opening of the mitochondrial permeability transition pore (mPTP),
which is associated with the release of cytochrome c and the collapse of the membrane potential
and leads to cell death [43,44]. We have previously reported that MPC-induced cardioprotection is
associated with improved mitochondrial function (greater complex I activity and ATP content and
less cyt c release) in a similar model, therefore supporting the concept of MPC-induced mitochondrial
preservation [45]. Interestingly, evidence exists to support a role for AMPK in the inhibition of mPTP
opening [32], which is consistent with a role for AMPK in the cardioprotection observed in HiR MPC
hearts. When phosphorylated, GSK3β, a downstream target of Akt and Erk, inhibits the opening of the
mPTP [46]. Even though mitochondrial damage was reduced in HiR vs. LoR MPC hearts, as indicated
by lower cyt c release, this was not reflected by GSK3β phosphorylation, suggesting that mitochondrial
preservation in HiR MPC hearts was not mediated by the RISK pathway. Additionally, we measured
STAT3 phosphorylation as a representative of the SAFE pathway. Phosphorylation was not different
among experimental groups, indicating that SAFE pathway activation is not involved in the improved
recovery observed in HiR vs. LoR MPC hearts.
As the perfusate levels of pro- and anti-inflammatory cytokines are expected to be low to
undetectable in our experimental setup [47], we have determined their cardiac content. TNFα tissue
content tended to be reduced in HiR compared to LoR MPC hearts. TNFα is part of the innate immune
system and also initiates cardioprotective signaling pathways. Briefly, low TNFα doses limit IRI,
Int. J. Mol. Sci. 2020, 21, 964 11 of 18
whereas higher TNFα doses increase infarct size when given before ischemia [48]. Interestingly, AMPK
also plays an acute anti-inflammatory role [23]. Reduced TNFα content in HiR vs. LoR MPC hearts
further supports greater AMPK activation in HiR MPC hearts. Finally, the induction of mPTP opening
and release of cytochrome c by TNFα has been reported previously [49]. This is consistent with our
findings of a lower cytochrome c release and lower TNFα content at early reperfusion in HiR vs. LoR
MPC hearts. Moreover, TNFα can initiate the SAFE pathway [50]; however, differing TNFα in HiR and
LoR MPC hearts was not reflected in STAT3 phosphorylation levels.
This study does possess some limitations. Our experimental (ex-situ) model and the specific
conditions were chosen in order to limit variability and strictly control the energy substrate availability
and duration and temperature of ischemia to simulate DCD conditions; however, it does not incorporate
the physiologic changes in the body following withdrawal of life sustaining therapy (typical DCD heart
donor), such as the catecholamine storm or pulmonary vasoconstriction leading to a pressure-volume
overload in the right heart [51,52]. Furthermore, although we provide new information about potential
mechanisms of MPC-mediated cardioprotection, additional studies are required to fully characterize
the precise molecular causes of MPC-induced effects. For example, specific AMPK inhibition at
reperfusion onset used in parallel with MPC or studies in hypoxia/reoxygenation cell culture models
could help to elucidate the cardioprotective effects of MPC. Pressure-volume loop analysis was not
used in this study and could add further information about heart function.
4. Materials and Methods
4.1. Ethics Statement
All experimental procedures were carried out in compliance with the European Convention for
Animal Care and approved by the Swiss animal welfare authorities and the Ethics Committee for
Animal Experimentation, Berne, Switzerland (Veterinärdienst des Kantons Bern; BE59/14; approval:
18.08.2014). Surgery was performed under general anesthesia, and all efforts were made to minimize
animal suffering.
4.2. Isolated Heart Perfusions
An isolated heart model of DCD heart transplantation was used, as previously reported [26,45,
47,53,54], with male Wistar rats (Janvier Labs, Le Genest-Saint-Isle, France) of 10 to 11 weeks of age
to ensure mature cardiac metabolism [55] and to represent young, adult human DCD donors. Rats
were housed under standard conditions at a controlled room temperature with a 12-h light–dark
cycle and access to water and food ad libitum. After random assignment to experimental groups
(in alternating fashion), the rats were anaesthetized intraperitoneally using 100 mg/kg ketamine
(Narketan®, Vetoquinol AG, Bern, Switzerland) and 10 mg/kg xylazine (Xylapan®, Vetoquinol AG,
Bern, Switzerland). As soon as the pedal reflex had disappeared, the hearts were excised and
cannulated on the perfusion system. Series A: Hearts first underwent 20 min of baseline working
mode perfusion with modified KHB buffer (containing 118 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4,
1.25 mM CaCl2·2H2O, 1.2 mM MgSO4·7H2O, 25 mM NaHCO3 and 11 mM glucose, supplemented with
1.2 mM palmitate/3% BSA and 0.5 mM lactate; gassed with 95% O2- 5% CO2). Thereafter, hearts were
subjected to 30 min global, no-flow, normothermic (37 ◦C) ischemia. The first ten minutes of reperfusion
following ischemia were performed in Langendorff/unloaded mode; subsequently the hearts were
switched to working mode for the following 50 min reperfusion (reperfusion buffer: modified KHB
buffer without addition of palmitate/BSA and lactate; Figure 8). Following ischemia, hearts were
either subjected to mechanical postconditioning (MPC; two cycles of 30 s reperfusion/30 s ischemia), or
directly reperfused (ischemia reperfusion, IR). In addition, a non-ischemic control group (no ischemia,
NI) was generated by prolonging the aerobic, baseline perfusion conditions for the equivalent time
of ischemia, followed by reperfusion as described above. Series B: Hearts were perfused using the
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three protocols described above, but stopped after a total of 15 min reperfusion for molecular analyses.
For glycogen content measurements, an additional group of hearts was stopped directly after ischemia.
Buffer samples from preload and coronary effluent were regularly taken throughout the perfusion
protocol and stored at −20 ◦C until analyzed.
As soon as the perfusion protocol was finished, perfusate lines to the heart were clamped and the
heart was immediately frozen with Wollenberger clamps cooled in liquid nitrogen. The heart was then
put into liquid nitrogen and stored at −80 ◦C until needed.
Figure 8. Experimental protocol. Hearts underwent 20 min of baseline, working-mode (loaded)
perfusion, followed by either 0 or 30 min of warm, global ischemia, and reperfusion (10 min unloaded
followed by working-mode (loaded) perfusion). In the treatment group, mechanical postconditioning
(MPC) was performed immediately following ischemia (two cycles of 30 s reperfusion/30 s ischemia),
which led to the emergence of two subgroups, referred to as HiR and LoR MPC. In Perfusion Series A,
hearts were reperfused for a total of 60 min for the measurement of contractile and metabolic recovery
(glycolysis, glucose oxidation, lactate, glycogen, glucose uptake). In Perfusion Series B, hearts were
treated identically, but were stopped after 15 min reperfusion for the analysis of key intracellular
signaling pathways. Circulating markers of mitochondrial and cellular damage, as well as oxygen
efficiency were also measured in this series of hearts. HiR, high recovery; IR, ischemia reperfusion;
LoR, low recovery; NI, no ischemia.
4.3. Functional Data Collection
To obtain data for cardiac function, a micro-tip pressure catheter (Millar, Houston, TX, USA) placed
in the left ventricle was used to continuously measure heart rate (HR), peak systolic pressure, developed
pressure (DP), minimum and maximum first derivatives of left ventricular pressure (dP/dt min and
dP/dt max). Left ventricular work (LV work) was calculated as previously described [45,47,53,54]:
DP × HR.
Flowmeters (Transonic Systems Inc., Ithaca, NY, USA) were used to measure perfusate flows in
preload and afterload lines, to determine coronary flow and cardiac output.
All data were recorded using a PowerLab data acquisition system (ADInstruments, Spechbach,
Germany).
4.4. Rates of Glycolysis and Glucose Oxidation
Radiolabeled glucose ([5-3H]glucose and [U-14C ]glucose; PerkinElmer, Waltham, MA, USA) was
added into the reperfusion buffer in an air-tight perfusion system with a hyamine hydroxide CO2
trap. Buffer samples were taken at various reperfusion time points and stored at −20◦C until analyzed.
Protocols for the measurement of glycolysis and glucose oxidation are described elsewhere [26,56].
Wet/dry weight ratio was used to normalize values.
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4.5. Cytochrome c, Cardiac Troponin I and Heart-Type Fatty Acid Binding Protein
10 min reperfusion buffer samples from Series B were used for ELISA measurements of cyt c (R&D
Systems, Minneapolis, MN, USA), cTnI (Life Diagnostics, West Chester, PA, USA) and H-FABP (Life
Diagnostics, West Chester, PA, USA). For all of these measurements, cardiac release was calculated as:
C(t) ×Vt
T ×HW
(1)
C = concentration in recirculating buffer, HW = heart weight, t = time point of interest, V = buffer
volume, T = perfusion duration
4.6. Lactate
Buffer samples from 0, 5, 10, 20, and 60 min reperfusion from Series A were measured with a
lactate assay kit (Sigma-Aldrich, St. Louis, MO, USA). Lactate accumulation was calculated as:
C(t) ×Vt −C(t0) ×V0
HW
(2)
C = concentration in recirculating buffer, HW = heart weight, t = time point of interest, V = buffer
volume, Wet/dry weight ratio was used to normalize.
4.7. Cardiac Oxygen Consumption and Oxygen Efficiency
Oxygen consumption was determined using the Cobas b 123 blood-gas analyzer (Roche, Basel,
Switzerland). Cardiac oxygen consumption was calculated as:
(CCE(t) −CPL(t)) ×CF(t)
HW
(3)
Cardiac oxygen efficiency was calculated as:
LV work (t)
O2C (t)
(4)
C = concentration, CE = coronary effluent, CF = coronary flow, HW = heart weight, LV work = left
ventricular work, O2C = oxygen consumption, PL = preload, t = time point of interest
4.8. Glycogen Content
Myocardial glycogen tissue content was determined using a spectrophotometric glucose assay kit
(Sigma-Aldrich, St. Louis, MO, USA) as previously described [26,57]. Wet/dry weight ratio was used
to normalize.
4.9. Glucose Uptake
Glucose uptake over the 60 min reperfusion period was calculated at as the sum of glucose that
passed through glycolysis and glucose that was incorporated into glycogen (glycogen (60 min) −
glycogen (mean end-ischemia)).
4.10. Phosphorylation of Key Signaling Molecules
In order to measure the phosphorylation status of key signaling molecules, Western blots
were performed according to the protocol described earlier [47]. The following antibodies were
obtained from Santa Cruz Biotechnology (Dallas, TX, USA): anti-GSK3β and anti-IRβ, others from Cell
Signaling Technology (Danvers, MA, USA): anti-AMPKα, anti-phospho-(Thr172)-AMPKα, anti-ACC,
anti-phospho-(Ser79)-ACC, anti-Akt, anti-phospho-(Ser473)-Akt, anti-AS160, anti-phospho-(Thr642)-
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AS160, anti-phospho-(Ser9)-GSK3β, anti-ERK1/2, anti-phospho-(Thr202/Tyr204)-EKR1/2, anti-STAT3,
anti-phospho-(Tyr705)-STAT3, anti-p38 MAPK, anti-phospho-(Thr180/Tyr182)-p38 MAPK, anti-mTOR,
anti-phospho-(Ser2448)-mTOR, anti-p70S6K, anti-phospho-(Thr389)-p70S6K, anti-4E-BP1, anti-
phospho-(Thr37/46)-4E-BP1, anti-raptor, anti-phospho-(Ser792)-raptor. Values for phosphorylated and
total proteins were normalized to the loading control IR-β or Akt.
4.11. Cytokine Content
Tissue measurements at 15 min reperfusion (Series B) of TNFα, IL-6 and interleukin 10 (IL-10) were
performed with ELISA kits (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions.
Tissue lysates were prepared as described for Western blots and results normalized by protein content.
4.12. Statistical Analysis
All values are expressed as mean ± standard deviation or as median, 25–75 percentiles and
range (box-and-whiskers). Statistical tests were performed for IR vs. NI, HiR MPC and LoR MPC,
as well as between HiR MPC and LoR MPC. For baseline parameters, experimental groups within each
perfusion series were compared, and corresponding values between perfusion Series A and B were
compared. All statistical analyses were performed with GraphPad Prism 7 (GraphPad Software, Inc.,
La Jolla, CA, USA). Cumulative rates of glycolysis and glucose oxidation were compared using linear
regressions. Kruskal–Wallis tests were employed for an overview of differences between experimental
groups. Afterwards, when significant overall results were observed, comparisons between groups
of particular interest at specific time points were performed with Mann–Whitney analyses. p-values
were all two-tailed and adjusted for multiple comparisons (modified sequential rejective Bonferroni
procedure [58]). With this approach, families of parameters, rather than individual parameters, are
considered for p-value correction in order to prevent an overly severe correction [58]. To do so, three
families of parameters were considered: baseline physiologic parameters, hemodynamic parameters,
and biochemical parameters. Corrected p-values are reported and considered statistically significant
if <0.05.
5. Conclusions
We investigated the heart’s endogenous metabolic and molecular conditioning mechanisms by
analyzing differences between hearts that responded positively and negatively to MPC. We reported
that MPC is not a safe strategy and should therefore not be applied to cardiac grafts obtained with
DCD. The existence of two subgroups in our study provided the opportunity to directly compare
high- vs. low- recovery hearts that were all subjected to MPC, and can thereby aid in pinpointing
critical protective mechanisms, while eliminating MPC-associated changes that do not contribute to
cardioprotection. Greater post-ischemic glucose uptake and glycolysis accompanied cardioprotective
MPC vs. deleterious MPC, which may result from prolonged AMPK (indicated by greater raptor
phosphorylation) and increased AS160 phosphorylation. Furthermore, MPC-induced cardioprotection
was associated with less mitochondrial damage and a trend for lower pro-inflammatory cytokine
content vs. LoR MPC (Figure 7). These aspects should help with the development and optimization of
effective cardioprotective reperfusion treatments for DCD hearts. Given the pre-ischemic treatment
limitations and use of ex-situ technology in DCD heart transplantation, controlled reperfusion strategies
hold great promise to limit IRI and ensure high graft quality. Ultimately, with a widespread adoption
of DCD heart transplantations, transplant activity could be increased by 15–33% [6,7] and hopefully
decrease waiting list mortality.
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Abbreviations
4E-BP1 4E-binding protein 1
ACC acetyl-CoA carboxylase
AMPK 5′AMP-activated protein kinase
AS160 Akt substrate of 160 kDa
cTnI cardiac troponin I
Cyt c cytochrome c
DCD donation after circulatory death
DP developed pressure
dP/dt max maximum first derivative of left ventricular pressure
dP/dt min minimum first derivative of left ventricular pressure
Erk1 extracellular signal-regulated kinase 1
GSK3β glycogen synthase kinase 3 beta
H-FABP heart-type fatty acid binding protein
HiR high recovery
HR heart rate
IL-6 interleukin 6
IL-10 interleukin 10
IRβ insulin receptor β
IRI ischemia reperfusion injury
LoR low recovery
LV work left ventricular work
MPC mechanical postconditioning
mPTP mitochondrial permeability transition pore
mTOR mammalian target of rapamycin
O2C cardiac oxygen consumption
p38 MAPK p38 mitogen-activated protein kinase
p70S6K ribosomal protein S6 kinase
PI3K phosphoinositide 3-kinase
raptor regulatory associated protein of mTOR
RISK reperfusion injury salvage kinase
SAFE survivor activating factor enhancement
STAT3 signal transducer and activator of transcription 3
TNFα tumor necrosis factor alpha
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